The TP53 gene, tobacco exposure, and lung cancer

Of the various genetic alterations in lung cancer, the abnormalities of the TP53 gene (p53) are among the most frequent and important events. Because of its importance, many aspects of TP53 have been studied, including preneoplastic lesions and TP53as a marker for early detection and prognosis and as a therapeutic option. We summarize recent knowledge of TP53 in lung cancer with a special emphasis on the relationship between smoking exposure (e.g, cigarette, etc.) and specific mutational pattern of TP53by analyzing the latest version of the International Agency for Research on Cancer (IARC) database on TP53 mutations in human cancer. Our analysis confirmed several other studies showing significant differences in the frequencies of G:C to T:A transversions between ever‐smokers and never‐smokers. Furthermore, when comparing the mutational spectrum by gender, important differences were noted between male and female never‐smokers. We concluded that the previously noted G:C to T:A transversions were mainly due to female smokers having a high frequency of these changes compared to female never‐smokers. There was no relationship between adenocarcinomas and squamous cell carcinomas independent of gender. We also examined the seven codons which have been previously identified as hot spots, that is, the sites of frequent G:C to T:A transversions in smoking‐related lung cancers. However, there was no specific codon which was strongly related to smoke exposure despite a moderate relationship. We considered the term “warmspot” may be more appropriate. While mutations of TP53 are frequent in lung cancers, further investigation is necessary to understand their role for lung carcinogenesis, especially as they relate to gender differences, and to translate our laboratory knowledge to clinical applications. Hum Mutat 21:229–239, 2003. © 2003 Wiley‐Liss, Inc.

[1]  Y. Inayama,et al.  Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. , 1995, The American journal of pathology.

[2]  K. Müller,et al.  German uranium miner study--pathological and molecular genetic findings. German Uranium Miner Study, Research Group Pathology. , 1999, Radiation research.

[3]  J. Minna,et al.  Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. , 1992, Oncogene.

[4]  J. Roth,et al.  Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.

[5]  Chinfei Chen,et al.  Gender difference in DNA adduct levels among nonsmoking lung cancer patients , 2001, Environmental and molecular mutagenesis.

[6]  U. Pastorino,et al.  Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. , 1992, Cancer research.

[7]  J. Testa,et al.  The pathogenesis of mesothelioma. , 2002, Seminars in oncology.

[8]  C. Harris,et al.  Radon and lung carcinogenesis: mutability of p53 codons 249 and 250 to 238Pu alpha-particles in human bronchial epithelial cells. , 1997, Carcinogenesis.

[9]  S. Rodin,et al.  Human lung cancer and p53: the interplay between mutagenesis and selection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[11]  Thierry Soussi,et al.  The UMD-p 53 Database : New Mutations and Analysis Tools , 2003 .

[12]  J. Minna,et al.  Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Y. Miller,et al.  Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. , 1997, The Journal of clinical investigation.

[14]  W. Whong,et al.  Distribution of p53 and K-ras mutations in human lung cancer tissues. , 1997, Carcinogenesis.

[15]  O. V. Paklina,et al.  [Atypical adenomatous hyperplasia of the lung]. , 2000, Arkhiv patologii.

[16]  J. Jett,et al.  Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. , 1995, Carcinogenesis.

[17]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[18]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[19]  Takaaki Ito,et al.  Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. , 1999, American journal of clinical pathology.

[20]  T. Mitsudomi,et al.  Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Jen,et al.  Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. , 2000, Cancer research.

[22]  I. Wistuba,et al.  Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas , 2000, International journal of cancer.

[23]  J. Nikliński,et al.  Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. , 2001, The European respiratory journal.

[24]  C. Harris,et al.  p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. , 1996, Carcinogenesis.

[25]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[26]  M. Olivier,et al.  TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. , 2001, Mutagenesis.

[27]  T. Allen-Mersh,et al.  Identification of carcinoembryonic antigen-producing cells circulating in the blood of patients with colorectal carcinoma by reverse transcriptase polymerase chain reaction. , 1996, Gut.

[28]  Jing Chen,et al.  Distribution of p 53 and Kras mutations in human lung cancer tissues , 1997 .

[29]  W. Travis,et al.  Lung cancer , 1995, Cancer.

[30]  Thierry Soussi,et al.  The UMD‐p53 database: New mutations and analysis tools , 2003, Human mutation.

[31]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[32]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.

[33]  K. Takami,et al.  Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs , 1998, Journal of surgical oncology.

[34]  T Paschke,et al.  Analysis of different versions of the IARC p53 database with respect to G-->T transversion mutation frequencies and mutation hotspots in lung cancer of smokers and non-smokers. , 2000, Mutagenesis.

[35]  J. Herman,et al.  Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.

[36]  J. Roth,et al.  A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. , 1993, Cancer research.

[37]  J. Minna,et al.  Molecular changes in the bronchial epithelium of patients with small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  C. Harris,et al.  p53 and K-ras mutations in lung cancers from former and never-smoking women. , 2001, Cancer research.

[39]  E. Wynder,et al.  Differences in lung cancer risk between men and women: examination of the evidence. , 1996, Journal of the National Cancer Institute.

[40]  K. Müller,et al.  p53 gene mutation analysis in tumors of patients exposed to alpha-particles. , 1997, Carcinogenesis.

[41]  C. Harris,et al.  Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. , 2001, Cancer research.

[42]  R. Hruban,et al.  Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.

[43]  P. Herrlich,et al.  Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. , 1995, Gut.

[44]  N. Bouck.  P53 and angiogenesis. , 1996, Biochimica et biophysica acta.

[45]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[46]  J. Gimferrer,et al.  Atypical adenomatous hyperplasia of the lung problems in operative management. , 2000, Lung cancer.

[47]  R. Herrmann,et al.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Giatromanolaki,et al.  p53 and angiogenesis in non-small-cell lung cancer. , 1998, British Journal of Cancer.

[49]  R. Hruban,et al.  p53 alterations in atypical alveolar hyperplasia of the human lung. , 1998, Human pathology.

[50]  S. Norell,et al.  Workbook of Epidemiology , 1995 .

[51]  北口 聡一.  Proliferative activity, p53 expression and loss of heterozygosity on 3p, 9p and 17p in atypical adenomatous hyperplasia of the lung , 1998 .

[52]  R. Metcalf,et al.  p53 protein accumulates frequently in early bronchial neoplasia. , 1993, Cancer research.

[53]  西﨑 正彦.  Recombinant adenovirus expressing wild-type p53 is antiangiogenic : a proposed mechanism for bystander effect , 2000 .

[54]  J. Minna,et al.  Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.

[55]  Richard Doll,et al.  Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies , 2000, BMJ : British Medical Journal.

[56]  P. Hainaut,et al.  Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.

[57]  C. Harris,et al.  Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. , 1996, Preventive medicine.

[58]  W. Travis,et al.  Neuroendocrine Tumors of the Lung With Proposed Criteria for Large‐Cell Neuroendocrine Carcinoma: An Ultrastructural, Immunohistochemical, and Flow Cytometric Study of 35 Cases , 1991, The American journal of surgical pathology.

[59]  G. Jacobson,et al.  Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas. , 1999, Journal of clinical pathology.

[60]  B. You,et al.  p53 gene mutations in asbestos associated cancers. , 1998, Biomedical and environmental sciences : BES.

[61]  J. Roth,et al.  High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. , 1994, Cancer gene therapy.

[62]  Jack A. Taylor,et al.  p53 and K-ras in radon-associated lung adenocarcinoma. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[63]  J. Jen,et al.  Mutations in Non-Small Cell Lung Cancer p 53 Frequency of Alcohol Consumption and Cigarette Smoking Increase the Updated , 2000 .

[64]  Yung‐Chie Lee,et al.  Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Tang,et al.  Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. , 2000, Journal of the National Cancer Institute.

[66]  Stephen S Hecht,et al.  Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. , 2002, The Lancet. Oncology.

[67]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[68]  Reply to the contribution of Hainaut, Olivier and Pfeifer (TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database) , 2001 .

[69]  Molecular Damage in the Bronchial Epithelium of Current and Former Smokers , 1997 .

[70]  P. Laurent-Puig,et al.  TP53 and head and neck neoplasms , 2003, Human mutation.

[71]  E. Mark,et al.  Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[72]  K. Bielawski,et al.  p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer , 2002, Journal of Cancer Research and Clinical Oncology.

[73]  G. Rechavi,et al.  Absence of p53 mutations in malignant mesotheliomas. , 1997, American journal of respiratory cell and molecular biology.

[74]  K. Kerr,et al.  Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53, and c‐erbB‐2 expression , 1994, The Journal of pathology.

[75]  H. Bartsch,et al.  Analysis of radon-associated squamous cell carcinomas of the lung for ap53 gene hotspot mutation , 2000, British Journal of Cancer.

[76]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[77]  T. Soussi,et al.  Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. , 1994, Chest.

[78]  K. Vähäkangas.  TP53 mutations in workers exposed to occupational carcinogens , 2003, Human mutation.

[79]  I. Wistuba,et al.  Genetic changes in the spectrum of neuroendocrine lung tumors , 1999, Cancer.

[80]  J. Nikliński,et al.  Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. , 2001, Lung cancer.

[81]  L. Mao.  Molecular abnormalities in lung carcinogenesis and their potential clinical implications. , 2001, Lung cancer.

[82]  C. Prives,et al.  The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells , 2002, Oncogene.

[83]  E. Dmitrovsky,et al.  Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. , 1995, Cancer research.

[84]  S. Payne,et al.  'Smoke like a man, die like a man'?: a review of the relationship between gender, sex and lung cancer. , 2001, Social science & medicine.